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Abstract 21 
Hyperlipidemia starts at a pediatric age and represents an unquestionable risk factor for 22 
cardiovascular disease. Modulation of the intestinal microbial ecosystem (IME), in principle, can 23 
ameliorate lipid profiles. In this study, we characterized the IME of children and adolescents with 24 
primary hyperlipidemia by analyzing fecal samples through 16S rRNA gene profiling (n=15) and 25 
short chain fatty acid (SCFA) quantification (n=32). The same analyses were also carried out on 26 
age-matched normolipidemic controls (n=15). Moreover, we evaluated the modulatory effect of 27 
regular hazelnut intake (approximately 0.43 g of hazelnuts with skin per kg of body weight) on the 28 
IME of 15 children and adolescents with hyperlipidemia for eight weeks. We found alterations of 29 
numerous operational taxonomic units (OTUs) potentially associated with SCFA-producing 30 
bacteria and reductions in the fecal levels of acetate, butyrate and propionate in hyperlipidemic 31 
subjects. Furthermore, we observed that an eight-week hazelnut intervention may induce limited 32 
changes in fecal microbiota composition but can significantly modulate the fecal levels of 33 
predominant intestinal SCFAs, such as acetate. Finally, correlation analyses indicated that changes 34 
in lipidemic parameters are linked to modifications of the abundance of specific bacterial taxa, such 35 
as the families Lachnospiraceae and Ruminococcaceae and the genera Akkermansia, Bacteroides, 36 
Roseburia, and Faecalibacterium. This study suggests that children and adolescents with primary 37 
hyperlipidemia possess an altered IME. The promising results presented here support the need for 38 
future dietary interventions aimed at positively modulating the IME of hyperlipidemic subjects. 39 
Key words: intestinal microbiota, 16S rRNA gene profiling, short chain fatty acids, hazelnuts, 40 
primary hyperlipidemia, children.  41 
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Background 42 
Hyperlipidemia is comprehensively defined as a lipoprotein metabolism disorder mainly manifested 43 
by increases in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and triglyceride 44 
concentrations. Hyperlipidemia may either be the result of a genetic defect in lipid metabolic 45 
pathways (primary) or secondary to underlying diseases. It may start at a pediatric age and 46 
represents an unquestionable risk factor for cardiovascular disease (D'Adamo et al. 2015).  47 
Dietary interventions appear to be a promising strategy for managing premature hyperlipidemia. 48 
For instance, the intake of a fiber-containing food supplement was shown to reduce total 49 
cholesterol, LDL-C levels, and apolipoprotein B in hypercholesterolemic children (Guardamagna et 50 
al. 2013). In addition, daily consumption of yogurt supplemented with phytosterols modulated lipid 51 
profiles by reducing LDL-C (Guardamagna et al. 2011a). In another trial, a probiotic formulation 52 
resulted in decreased LDL-C and improvements in triglyceridemia and HDL cholesterol (HDL-C) 53 
levels (Guardamagna et al. 2014). Mechanisms that support the potential efficacy of the 54 
abovementioned interventions include the suppression of liver cholesterol synthesis (Guardamagna 55 
et al. 2011b), reduction of intestinal cholesterol absorption (Guardamagna et al. 2011a), and 56 
production of conjugated linoleic acid in the gut (Guardamagna et al. 2014). 57 
In principle, modulation of the gut microbiota could represent an additional strategy for the 58 
amelioration of lipid profiles. In fact, expanding scientific evidence indicates that the gut microbiota 59 
mediates pathophysiological mechanisms that alter lipid metabolism and other related metabolic 60 
traits (Ghazalpour et al. 2016). Particularly, the intestinal microbiota has been recognized as a 61 
metabolically active endocrine organ of the human superorganism that can be a therapeutic target 62 
for hyperlipidemia and associated cardiometabolic diseases (Brahe et al. 2016; Ghazalpour et al. 63 
2016). In fact, numerous metabolites produced by intestinal bacteria, such as 64 
trimethylamine/trimethylamine-N-oxide, secondary bile acids, catecholamines, and short chain fatty 65 
acids (SCFAs), are not simply absorbed and metabolized by human cells for energy needs but also 66 
4 
 
act as hormone-like factors that impact numerous aspects of host physiology (Boulange et al. 2016; 67 
Brown and Hazen 2015). Particularly, SCFAs, including acetate, butyrate, propionate and valerate, 68 
in addition to being used an energy source by the colonic epithelium (in particular, butyrate), are 69 
sensed by dedicated receptors on numerous diverse cell populations around the human body, 70 
resulting in the regulation of energy metabolism, insulin sensitivity, and immune responses (Brown 71 
et al. 2003; Brown and Hazen 2015; De Vadder et al. 2014; Gao et al. 2009; Kimura et al. 2013; 72 
Saemann et al. 2000). 73 
Although altered microbiota composition (generally called “dysbiosis”) has been associated with 74 
diseases that are characterized by hyperlipidemia, such as obesity (Kobyliak et al. 2016), diabetes 75 
(Yamaguchi et al. 2016), metabolic diseases (Woting and Blaut 2016) and non-alcoholic fatty liver 76 
disease (Wang et al. 2016), the intestinal microbial ecosystem (IME) has never been thoroughly 77 
investigated in young people with inherited hyperlipidemia. 78 
Hyperlipidemic subjects could receive both specific and overall benefits by consuming dietary 79 
patterns/food products that can affect lipid metabolism through modulation of the intestinal 80 
microbiota. In this context, nuts have been suggested as lipid-lowering products due to their 81 
richness in unsaturated fats and other bioactive compounds (such as L-arginine, fiber, minerals, 82 
vitamin E, phytosterols and polyphenols), which may synergistically contribute to improving 83 
plasma lipid profiles and providing overall cardiovascular benefits (Ros 2015). In light of the above 84 
considerations, in this study, we characterized the IME of children and adolescents with primary 85 
hyperlipidemia by means of 16S rRNA gene profiling and short chain fatty acid (SCFA) 86 
quantification in fecal samples. Furthermore, the potential modulatory effects of regular hazelnut 87 
intake on microbiota composition and SCFA levels were investigated. Finally, we studied the 88 
potential correlations existing between the IME and hyperlipidemia-related clinical parameters. 89 
 90 
Materials and methods 91 
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Ethics approval and consent to participate. The study protocol conformed with the principles 92 
outlined in the Declaration of Helsinki and was approved by the Ethics Committee of the City of 93 
Health and Science University Hospital of Turin, Italy (EC:CS377). The protocol and aim of the 94 
study were explained in detail to all participants and their legal guardians; before participants were 95 
enrolled in the study, their guardians signed an informed consent. 96 
Participants. The volunteers considered in the present study were derived from a subgroup of 97 
children and adolescents with primary hyperlipidemia; they were aged between 7 and 17 years old 98 
and were participants in a national project aimed at characterizing this pediatric population (Deon et 99 
al. 2017b) and investigating the effect of regular intake of hazelnuts with skin for eight weeks on 100 
several markers related to lipid metabolism and oxidative stress (Deon et al. 2017a; Deon et al. 101 
2017b). The trial was registered at ISRCTN.com (identifier no. ISRCTN12261900). Subjects 102 
participating in the intervention study were recruited among patients receiving care at the 103 
Department of Health Science and Pediatrics at the University of Turin (Italy) after a screening for 104 
eligibility. In addition, 15 age-matched normolipidemic volunteers were recruited in the same area 105 
and time frame as the controls for microbial ecology analysis of fecal samples. The age and sex of 106 
the participants are shown in Table S1. 107 
The recruited hyperlipidemic subjects were asked to collect a stool sample before and after the 108 
intervention. Thirty-two stool samples were collected for analysis at baseline, but only 15 samples 109 
were available after eight weeks of hazelnut with skin (HZN+S) consumption. The effect of dietary 110 
intervention on the fecal microbiota composition was analyzed in 15 subjects, whereas the levels of 111 
SCFAs were evaluated in the whole group of children and adolescents with primary hyperlipidemia 112 
who provided stool samples at baseline.  113 
To be eligible, screened children and adolescents were required to be of normal weight with a 114 
diagnosis of primary hyperlipemia, including familial hypercholesterolemia (FH), familial 115 
combined hyperlipidemia (FCHL) or polygenic hypercholesterolemia (PHC), with total serum 116 
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cholesterol (TC) and/or triglycerides (TG) levels higher than age- and sex-specific 90th percentiles. 117 
The diagnostic criteria of primary hyperlipidemia were based on accepted international standards as 118 
previously reported (Guardamagna et al. 2009). FH was diagnosed in presence of LDL-C ≥95th 119 
percentile, parental LDL-C ≥190 mg dl-1, tendon xanthomas and/or cardiovascular disease 120 
(phenotype IIA). FCHL was diagnosed in children showing TC and/or TG >90th age- and sex-121 
specific percentiles with at least one parent affected by hypercholesterolemia, hypertriglyceridemia, 122 
or both (IIA, IV, or IIB phenotype, respectively) with concomitant individual and familial lipid 123 
phenotype variability. Children with LDL-C levels >90th percentile and a family history of 124 
dominant inherited hypercholesterolemia but who did not fulfill the biochemical international 125 
diagnostic criteria of FH or FCHL were diagnosed with PHC. Subjects were excluded if they had 126 
food allergies or a specific aversion to nut consumption, secondary hyperlipidemias, obesity (body 127 
mass index, BMI, ≥90th percentile, age and sex matched); renal, endocrine, liver or gastrointestinal 128 
disorders (e.g., diarrhea, inflammatory bowel disease, or irritable bowel syndrome) or chronic 129 
diseases requiring drug treatment (i.e., immunologic, neurologic, or oncohematologic disorders). 130 
Subjects were also excluded from the study if they were taking lipid-lowering treatments, 131 
antibiotics, or probiotic or prebiotic products one month prior to the first visit or if they had viral or 132 
bacterial enteritis two months before the first visit. 133 
Experimental design. All enrolled patients were following nutritional recommendations 134 
suggested for pediatric hyperlipidemia based on the cardiovascular health integrated lifestyle diet 135 
(CHILD-1) (Expert Panel on Integrated Guidelines for Cardiovascular et al. 2011). Nutritional 136 
recommendations were as follows: 55% of daily energy intake from carbohydrates, 15% from 137 
proteins, and 30% from fats (saturated fat 7-10%). Additional recommendations were that dietary 138 
cholesterol should be lower than 100 mg/1000 kcal (and no more than 300 mg/day) and soluble 139 
fiber intake should be 10-25 g/day. 140 
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Dietary intervention consisted of an 8-week intake of HZN+S. Subjects were provided with pre-141 
weighed vacuum-packed portions of Italian roasted Corylus avellana L. (cultivar ‘Tonda Gentile 142 
delle Langhe’ from Piedmont, Italy). The quantity of hazelnuts per packet was calculated by 143 
considering doses generally advised for adults and were adjusted to the children’s body weight 144 
(approximately 0.43 g kg-1 body weight up to a maximum of 30 g, which is the recommended daily 145 
dose for an adult). All participants were encouraged to maintain the same dietary pattern and 146 
lifestyle habits throughout the 8-week intervention study. Subjects were required to exclude the 147 
intake of other nuts, dried fruits, probiotic or prebiotic foods or supplements from one month before 148 
the beginning of the study until the end of the experiment. Traditional yogurt was allowed. To 149 
check compliance to dietary recommendations, subjects and their families were asked to fill in 150 
weekly food diaries as previously reported (Deon et al. 2017a).  151 
At baseline and at the end of the HZN+S intervention (0 and 8 weeks), each study participant 152 
underwent a medical examination after an overnight fast, during which biological samples and 153 
physical parameters (including height, weight and blood pressure measurements) were obtained. 154 
Serum levels of TC, HDL-C and TG were directly determined by an automatic biochemical 155 
analyzer (Olympus AU2700, Japan), whereas the LDL-C concentration was estimated using the 156 
Friedewald formula (LDL=TC-(HDL+TG/5)), and non-high density lipoprotein cholesterol (non-157 
HDL) was calculated by subtracting HDL-C from TC.  158 
The fecal samples were collected from each participant in a sterile plastic pot within 24 h before 159 
visits at baseline and following the HZN+S intervention. A single fecal sample was also collected 160 
from 15 age-matched controls. According to the recommendations for “storage conditions of 161 
intestinal microbiota matter in metagenomic analysis” (Cardona et al. 2012), participants were asked 162 
to deliver the fecal sample to the laboratory within 24 h. Upon delivery, stool samples were stored at 163 
-80°C until DNA extraction. Subjects were asked to return any uneaten HZN+S packages at the visit. 164 
Compliance was assessed by weighing returned packages and checking weekly food diaries. 165 
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Bacterial profiling of fecal microbiota. The bacterial community structure of fecal samples was 166 
determined by 16S ribosomal RNA gene profiling with Illumina MiSeq System at the Center for 167 
life – Nanoscience, Istituto Italiano di Tecnologia (Roma, Italy). Briefly, metagenomic DNA was 168 
extracted from 200 ± 10 mg of stool within 30 days from delivery by means of a PowerFecal DNA 169 
Isolation Kit (Mo Bio Laboratories, Cabru s.a.s., Biassono, Italy) according to the manufacturer’s 170 
specifications. A DNA fragment encompassing the V3 and V4 regions of the 16S rRNA gene was 171 
amplified from metagenomic DNA with the primer pair selected by Klindworth et al. in 172 
(Klindworth et al. 2013). The sequencing runs were multiplexed and barcode sequences were used 173 
to discriminate the samples. 16S rRNA gene sequence reads were analyzed through the 174 
bioinformatic pipeline Quantitative Insights Into Microbial Ecology (QIIME) version 1.7.0 using 175 
the last version of Greengenes (gg_13_5) as reference taxonomic database. We used a reference 176 
picking to cluster and assign the taxonomy to the reads. We add this information in the section 177 
Materials and Methods as suggested. Analysis of the α- and β-diversities were performed using 178 
QIIME. For α-diversity inverse Simpson, Chao1 and Shannon indexes were calculated. Concerning 179 
β-diversity, the UniFrac algorithm was used to obtain the phylogenetic information needed to 180 
generate the dissimilarity matrix. Bacterial abundances in each fecal sample were determined at the 181 
operational taxonomic unit (OTU) level. Sequence reads from 16S rRNA gene profiling have been 182 
deposited in the European Nucleotide Archive (ENA) of the European Bioinformatics Institute 183 
under accession code PRJEB10296. 184 
Quantification of fecal short chain fatty acids (SCFAs). SCFAs were quantified in the fecal 185 
samples collected from 32 subjects, including the 15 who completed the intervention trial. SCFA 186 
quantifications were performed as previously described (Gargari et al. 2016). In brief, stools (200 ± 187 
10 mg) were extracted in 10 ml of 0.001% HCOOH by vortexing for 1 min. The supernatant was 188 
then recovered through centrifugation at 1000 x g for 2 min at 4 °C. All extracts were stored at -20 189 
°C until UPLC-HR-MS analysis, which was carried out on an Acquity UPLC separation module 190 
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(Waters, Milford, MA, USA) coupled with an Exactive Orbitrap MS with an HESI-II probe for 191 
electrospray ionization (Thermo Scientific, San Jose, CA, USA). The ion source and interface 192 
conditions and other detailed information were as specified in (Gargari et al. 2016). The eluents 193 
were 0.001% HCOOH in MilliQ-treated water (solvent A) and CH3OH:CH3CN (1:1, v/v, solvent 194 
B); UPLC elution gradient: 0% B for 4 min, 0-15% B in 6 min, 15–20% B in 5 min, 20% for 13 195 
min, and then return to initial conditions in 1 min. The UPLC eluate was analyzed in full-scan MS 196 
in the range 50–130 m/z. The resolution was set at 50 K, the AGC target was 1E6, and the 197 
maximum ion injection time was 100 ms. The MS data were processed using Xcalibur software 198 
(Thermo Scientific). Five-point external calibration curves prepared with analytical grade SCFAs 199 
(Sigma-Aldrich, Milan, Italy) were adopted to quantify acetate, butyrate, isobutyrate, isovalerate, 200 
lactate, propionate, pyruvate, succinate, and valerate in fecal samples. SCFA concentrations were 201 
expressed in millimoles per kilogram of wet feces. 202 
Statistics. Statistical analyses were performed using R statistical software (version 3.1.2). A 0 203 
(zero) was given to any taxon that was not detected in a specific sample to enable comparisons. All 204 
statistical tests were performed considering three study populations: (i) hyperlipidemic subjects 205 
before HZN+S intake, (ii) hyperlipidemic subjects after HZN+S intake and (iii) normolipidemic 206 
subjects as controls. Differences in the microbiota composition of these populations were 207 
determined using a Wald test following DESeq2 (paired between the comparison of hyperlipidemic 208 
subject populations) read count normalization. After DESeq2 normalization, only OTUs with a 209 
number of reads higher than 5 in at least one quarter of the samples were considered for statistical 210 
analysis. Significant differences between groups of samples in β-diversity were assessed through 211 
the non-parametric statistical test ANOSIM (analysis of similarities). 212 
Differences in SCFA concentrations were evaluated by analyzing the data with a non-parametric 213 
Wilcoxon-Mann-Whitney test using paired data (when allowed). 214 
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The correlation analyses were carried out using Kendall and Spearman formulas with changes 215 
over the treatment in bacterial taxa abundances (DESeq2-normalized data), lipidemic profile data 216 
and fecal SCFA concentrations in hyperlipidemic subjects. 217 
Statistical significance was set at p≤0.05; the mean differences with 0.05<p≤0.10 were accepted 218 
as trends. When p value correction was applied, false discovery rate (FDR) adjustment was used. 219 
 220 
RESULTS 221 
16S rRNA gene profiling and SCFA quantification revealed significant differences in the fecal 222 
microbial ecosystem between hyperlipidemic and control subjects. A total of 13,830,110 223 
filtered high-quality sequence reads was generated (average of 153,668 ± 60,148 paired reads per 224 
sample). We identified a total of 109 bacterial families (100 in hyperlipidemic samples and 89 in 225 
controls) and 269 bacterial genera (244 in hyperlipidemic subjects and 193 in controls). We found a 226 
minimum number of 39 families and 69 genera and a maximum of 63 families and 110 genera per 227 
fecal sample in hyperlipidemic subjects; a minimum of 44 families and 80 genera and a maximum 228 
of 64 families and 113 genera were found in controls. Only approximately 15% of families (n=16) 229 
and 10% of genera (n=26) were detected in all 45 analyzed fecal samples; the same 16 families and 230 
26 genera were the only ones detected in all 30 hyperlipidemic fecal samples, whereas 30 families 231 
and 46 genera were found in all 15 control samples. These data suggest that bacterial composition 232 
varied more among hyperlipidemic samples than among control fecal samples, which was also 233 
evidenced by the analysis of β-diversity (Fig. 1). 234 
The analysis of β-diversity performed with the unweighted UniFrac algorithm evidenced a 235 
significant segregation of controls from hyperlipidemic samples (p<0.05 and number of 236 
permutations=99 according to ANOSIM test), which was principally led by the abundance of 237 
Faecalibacterium spp. and two unidentified Clostridiales genera (Fig. 1B). Also, the intrasample 238 
(α)-diversity analyzed through the Chao1 index evidenced a difference between hyperlipidemic and 239 
11 
 
control samples (Fig. 2). Specifically, Chao1, which estimates the abundance of OTUs in a single 240 
sample, was significantly higher in the control samples (p<0.001 according to unpaired Mann-241 
Whitney U test) than in the hyperlipidemic samples; nonetheless, we did not find any difference 242 
between the groups when we analyzed α-diversity with the inverse Simpson index, which estimates 243 
biodiversity also considering OTU evenness (Fig. 2B). In addition, microbiota diversity analyses 244 
failed to reveal age-related differences in the IME of volunteers (Fig. S1). 245 
Overall, the taxonomic composition of the fecal microbiota of both hyperlipidemic and control 246 
subjects was characterized by a dominance of Firmicutes bacteria (mean relative abundance of 67% 247 
in hyperlipidemic samples and 68% in controls; Fig. S2); particularly, three Clostridiales families, 248 
i.e., Lachnospiraceae, Ruminococcaceae, and an undefined family of the order, constituted more 249 
than 50% of all bacteria in both hyperlipidemic and control subjects (Fig. S2). In addition, the most 250 
abundant non-Firmicutes families were Bacteroidaceae (phylum Bacteroidetes, mean relative 251 
abundance of 17% in hyperlipidemic samples and 16% in controls) and Bifidobacteriaceae (phylum 252 
Actinobacteria, mean relative abundance of 7% in hyperlipidemic samples and 6% in controls; Fig. 253 
S2).  254 
To infer taxonomic signatures distinguishing the fecal microbiota structure of the 15 255 
hyperlipidemic participants and the 15 aged-matched normolipidemic controls, we performed a 256 
comparative analysis at the OTU level through the DESeq negative binomial distribution method. 257 
We found 229 OTUs whose abundance was significantly different between the two groups of 258 
subjects (Fig. S3 and Fig. 3): 193 OTUs were increased in the controls, whereas only 36 OTUs 259 
were increased in the hyperlipidemic samples (Fig. S3). Most of the OTUs belonged to the phylum 260 
Firmicutes and particularly to the families Ruminococcaceae and Lachnospiraceae; notably, 261 
controls were enriched in OTUs belonging to well-recognized butyrate producing bacteria, such as 262 
the genus Roseburia and the species Faecalibacterium prausnitzii. We also observed a significant 263 
reduction in an OTU ascribed to the species Akkermansia muciniphila in the hyperlipidemic 264 
samples. In addition, 23 OTUs belonging to the phylum Bacteroidetes were significantly enriched 265 
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in controls compared to hyperlipidemic samples, whereas only 3 Bacteroides OTUs were reduced 266 
(Fig. S3). 267 
Finally, the IME of enrolled children and adolescents was characterized through the 268 
quantification of 8 SCFAs and lactate in fecal samples by UPLC-HR-MS (Table S2). Specifically, 269 
we analyzed the data from the fecal samples of 15 hyperlipidemic subjects undertaking the hazelnut 270 
intervention together with 17 additional fecal samples from hyperlipidemic subjects at baseline. We 271 
found that the fecal levels of several SCFAs were significantly different between hyperlipidemic 272 
and control subjects; specifically, hyperlipidemia was associated with significantly lower 273 
concentrations of acetate (p<0.001 according to unpaired Mann-Whitney U test), butyrate (p<0.01) 274 
and propionate (p<0.01), whereas lactate (p<0.05), isobutyrate (p<0.01) and pyruvate (p<0.001) 275 
were significantly increased compared to control subjects (Fig. 4). Notably, the fecal levels of 276 
acetate (p<0.001), propionate (p<0.001) and butyrate (as a trend, p=0.085) were significantly lower 277 
in hyperlipidemic samples when we also included data collected in a previous study on 25 healthy 278 
adult volunteers in the analysis (Gargari et al. 2016) (Fig. S4); these volunteers were considered to 279 
be an additional reference for healthy/physiological fecal SCFA levels, knowing that the human gut 280 
microbiota acquires an adult-like structure by the third year of life (Lozupone et al. 2013). The 281 
levels of valerate, isovalerate and succinate were not significantly different between the groups. 282 
Overall, these data suggest that hyperlipidemia is potentially associated with gut microbiota 283 
dysbiosis, which can be characterized by the alteration of numerous OTUs associated with SCFA-284 
producing bacteria and the reduction of fecal levels of acetate, butyrate and propionate. 285 
 286 
Hazelnut intake induced limited changes in bacterial abundances but modulated SCFA levels 287 
in feces. The α- and β-diversity of fecal samples were not significantly affected by the eight-week 288 
hazelnut intervention (Fig. 1 and Fig. 2). Furthermore, we did not find any OTU that was modified 289 
with an FDR adjusted p value (padJ) lower than the significance limit of 0.05 (Fig. S5). Only an 290 
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undefined Clostridiales OTU, which was reduced after the intervention, displayed a padJ value 291 
lower than 0.1 (Fig. S5). 292 
Subsequently, we quantified the fecal level of 8 SCFAs and lactate after hazelnut consumption in 293 
14 hyperlipidemic subjects that completed the intervention (Fig. 4). We found that acetate increased 294 
significantly over the intervention (p<0.05 according to paired Wilcoxon test). An increasing trend 295 
(p=0.079) was also observed for propionate. 296 
Overall, these results indicate that the eight-week intervention with hazelnut may induce limited 297 
changes in the fecal microbiota composition but can significantly modulate fecal levels of the 298 
predominant intestinal SCFA acetate. 299 
 300 
The modification of several taxa of the fecal microbiota correlates with changes in the host’s 301 
hyperlipidemia biomarkers. We performed correlation analyses between the variations observed 302 
in the abundance of bacterial taxa and changes in the lipid profile of hyperlipidemic subjects. 303 
Specifically, we considered the serum levels of total cholesterol (TC), low-density lipoprotein 304 
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL cholesterol, and 305 
triglycerides (TG). We found that lipidemic parameters changed over the intervention and were 306 
associated with variations in 144 OTUs, 19 of which were significantly different between 307 
dyslipidemic and control samples (Fig. 5). We found an inverse correlation between the changes in 308 
TC and the variation of several Ruminococcaceae OTUs, particularly Faecalibacterium prausnitzii. 309 
The changes in HDL-C inversely correlated with fluctuations in the abundance of several 310 
Clostridiales and Collinsella OTUs; on the contrary, a positive correlation for HDL-C was observed 311 
with variations in a smaller number of Clostridiales and mostly Lachnospiraceae, including an OTU 312 
ascribed to the genus Roseburia. Only 15 OTUs were found to be correlated with LDL-C changes; 313 
13 of them (7 positively and 6 negatively correlated) were ascribed to the order Clostridiales. 314 
Notably, triglyceridemia was inversely correlated with the change of 22 OTUs ascribed to the genus 315 
Bacteroides, 3 Lachnospiraceae OTUs, 3 OTUs ascribed to the species F. prausnitzii, and 2 316 
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Akkermansia muciniphila OTUs. In contrast, triglyceridemia modifications were positively 317 
correlated with changes of 5 Coprococcus OTUs. 318 
Overall, these results indicate that lipid profiles of the hyperlipidemic subjects investigated here 319 
are linked to modifications of the abundance of specific taxa in the intestinal microbiota, such as the 320 
families Lachnospiraceae and Ruminococcaceae and the genera Akkermansia, Bacteroides, 321 
Roseburia, and Faecalibacterium. 322 
 323 
DISCUSSION 324 
In this study, we show for the first time that young individuals with inherited hyperlipidemia may 325 
possess a dysbiotic gut bacterial ecosystem. We came to this result by comparing the IME of 326 
hyperlipidemic children and adolescents (ages ranging from 7 to 17 years old, mean age of 11) with 327 
the IME of age-matched normolipidemic controls (ages ranging from 5 to 17 years old, mean age of 328 
11). Although the age range was considered quite wide, spanning from early school-aged childhood 329 
to late adolescence, we did not observe age-related differences in the IME of volunteers (Fig. S1), 330 
which is in accordance with the scientific literature demonstrating that the intestinal microbiota of 331 
children reaches an adult state at approximately 3 years of age (Lozupone et al. 2013; Matamoros et 332 
al. 2013; Rodriguez et al. 2015). 333 
Notably, diet can play a leading role in shaping the gut microbiota (Amato et al. 2015; De 334 
Filippo et al. 2010); therefore, possible differences in eating behaviors between hyperlipidemic and 335 
normolipidemic counterparts could have been contributed to IME differences. However, we 336 
calculated through food diaries and food frequency questionnaires that macronutrient contributions 337 
to the overall diet were comparable between the two groups of subjects (data not shown). 338 
Particularly, fiber intake was at the lower range of CHILD-1 recommendations as previously 339 
published (Deon et al. 2017a). Moreover, children maintained their dietary behavior, even if a slight 340 
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increase in energy and fat intake (by approximately 100 kcal) was registered due to the hazelnut 341 
intervention. 342 
In general, the microbiota composition of subjects investigated here is in accordance with the 343 
literature, which shows that Firmicutes bacteria constitute between 50 and 80% of the taxa in the 344 
core intestinal microbiota of healthy adults, including Lachnospiraceae and Ruminococcaceae as the 345 
most abundant and metabolically active taxa (Jalanka-Tuovinen et al. 2011; Peris-Bondia et al. 346 
2011; Tap et al. 2009). Moreover, the fecal microbiota structure of all subjects included in this 347 
study is in accordance with a study that evidenced a similar dominance of Firmicutes in children 348 
following an urban Western lifestyle compared to children with a rural diet (De Filippo et al. 2010). 349 
Nonetheless, the results of the present study also evidenced that the fecal microbiota of 350 
hyperlipidemic subjects is characterized by the alteration of numerous operational taxonomic units 351 
(OTUs), many of which belong to the Clostridiales order, whereas several Bacteroidetes OTUs 352 
were found to be significantly reduced. Hyperlipidemia is a predisposing factor and an intrinsic 353 
feature of several diseases, such as obesity, in which a similar alteration of the microbiota has been 354 
observed. In fact, a number of studies have shown that obesity associated with dysbiosis enhances 355 
energy extraction from food and increases low-grade inflammation and is characterized by an 356 
increase of bacteria from the phylum Firmicutes (mainly Clostridiales) and a specific decrease in 357 
Bacteroidetes (Armougom et al. 2009; Baothman et al. 2016; Ley et al. 2006; Santacruz et al. 358 
2010). In addition, an enhanced Firmicutes/Bacteroidetes ratio has been associated with a high-359 
protein, high-fat Western diet (Amato et al. 2015) and distinguished European from African 360 
children aged 1–6 years old(De Filippo et al. 2010). 361 
Data on type 2 diabetes, which can be a hyperlipidemia-associated disease, indicated only a 362 
moderate degree of gut microbial dysbiosis and instead reported a ‘functional dysbiosis’ in which a 363 
decrease in the intestinal level of butyrate was observed (Tilg and Moschen 2014). The loss of 364 
butyrate producing bacteria and decreased butyrate levels in the gut have also been often reported in 365 
intestinal inflammatory conditions (Sokol et al. 2008; Van Immerseel et al. 2010). Accordingly, in 366 
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our study, compared to normolipidemic controls, we found in hyperlipidemic subjects a 367 
significantly reduced abundance of OTUs ascribed to well-recognized butyrate producing bacteria, 368 
such as Faecalibacterium prausnitzii and Roseburia spp. (Louis and Flint 2009), together with a 369 
significantly lower concentration of fecal butyrate. 370 
Butyrate is mostly produced by Clostridiales bacteria, whereas acetate and propionate are 371 
principally derived from the primary metabolism of members of the phylum Bacteroidetes 372 
(Macfarlane and Macfarlane 2003). In accordance with the observed lack of several Bacteroidetes 373 
OTUs, we found that the fecal levels of acetate and propionate were significantly decreased in 374 
hyperlipidemic subjects. Acetate and propionate produced by the gut microbiota are rapidly 375 
absorbed and reach the liver via the portal circulation, where they are used as an energy source 376 
(Canfora et al. 2015; den Besten et al. 2013) and participate in lipogenesis and gluconeogenesis, 377 
respectively (Canfora et al. 2015). There is experimental evidence suggesting that acetate and 378 
propionate may regulate cholesterol metabolism by decreasing the activity of hepatic 3-hydroxy-3-379 
methylglutaryl-CoA synthase (HMGCS) and reductase (HMGCR) (den Besten et al. 2013); in 380 
addition, acetate may increase cholesterol 7-α-hydroxylase (CYP7A1) (Fushimi et al. 2006; 381 
Rodwell et al. 1976). Notably, HMGCS and HMGCR are involved in the initial steps of cholesterol 382 
biosynthesis (Rodwell et al. 1976), whereas CYP7A1 participates in cholesterol-bile acid 383 
conversion (den Besten et al. 2013). It can be then argued that reduction of the intestinal levels of 384 
acetate and propionate in hyperlipidemic subjects may contribute to their altered cholesterol 385 
metabolism. Interestingly, in our study, following the dietary intervention with hazelnut, we 386 
observed a significant increase in acetate and a trend to rise of propionate levels with an assumed 387 
potential benefit for individuals with hyperlipidemia. At the same time, as previously reported 388 
(Deon et al. 2017a), hazelnut consumption significantly affected serum lipid profile (i.e., time effect 389 
reduction of LDL-C and non HDL-C and increase of HDL-C/LDL-C) and erythrocyte phospholipid 390 
fatty acid composition (i.e., increased levels of MUFAs, oleic acid and MUFAs/SFAs ratio). 391 
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In addition to the lower abundance of predominant intestinal SCFAs (acetate, butyrate and 392 
propionate, representing up to 95% of the SCFAs present in the colon), we found in hyperlipidemic 393 
fecal samples increased levels of lactate, isobutyrate and pyruvate. Lactate is produced by several 394 
members of the intestinal microbiota, such as lactic acid bacteria, bifidobacteria and enterobacterial 395 
species (e.g., E. coli). However, under normal physiological conditions, lactate does not accumulate 396 
in the colon since it is consumed by other intestinal microorganisms. Particularly, lactate is 397 
converted to butyrate by several gut commensals, such as Eubacterium hallii, Anaerostipes caccae 398 
and Roseburia intestinalis (Bourriaud et al. 2005; Duncan et al. 2004; Flint et al. 2015; Van den 399 
Abbeele et al. 2013), which are all members of the order Clostridiales. Therefore, an accumulation 400 
of lactate can be plausibly considered to be a metabolic signature of dysbiosis; accordingly, the 401 
shifts of bacterial metabolism from short chain fatty acid to lactate production and the resulting 402 
intraluminal pooling of lactate have been associated with pathological conditions (Bustos et al. 403 
1994; Huda-Faujan et al. 2010; Vernia et al. 1988). Reportedly, lactate is present at low 404 
concentrations (<3 mmol l-1) or is not detected in the feces of healthy individuals (Duncan et al. 405 
2007; Vernia et al. 1988), whereas concentrations up to 100 mmol l-1 have been reported in gut 406 
disorders (Hove et al. 1994; Vernia et al. 1988). Therefore, considering that in our study lactate 407 
exceeded the level of 1 mmol per kg of feces in only 5 out of 48 analyzed samples, the actual 408 
physiological significance of fecal lactate as detected here in hyperlipidemic subjects is 409 
questionable. 410 
Isobutyrate, which is produced in the gut by the degradation of amino acids, such as valine (Zarling 411 
and Ruchim 1987), has been found to be correlated with behavior changes induced by prebiotics in 412 
mice (Burokas et al. 2017), whereas pyruvate, which can derive from bacterial autolysis or exfoliated 413 
apical enterocytes, has been associated with inflammatory bowel disease (Huda-Faujan et al. 2010). 414 
However, the actual importance of the modification of these organic acids in the human gut is unclear, 415 
and the literature is too limited yet to allow a complete interpretation of our results. 416 
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Although the hazelnut intervention significantly modified the fecal levels of SCFAs, the 417 
abundances of bacterial taxa in the fecal microbiota were only mildly affected. The observed 418 
modifications of SCFA levels that occurred after hazelnut consumption may be plausibly explained 419 
by the intake of fiber derived from the overall diet, including the contribution of hazelnuts. 420 
However, the elaboration of dietary intake did not support such a hypothesis since fiber intake did 421 
not change following the intervention (i.e., approximately 10 g per day as a mean in this target 422 
population) (Deon et al. 2017a). Moreover, despite the fact that energy intake did not change 423 
following the regular consumption of hazelnuts, it should be underlined that increased intake of 424 
total fat (+5%) and monounsaturated fatty acids (+4.7%) was observed (Deon et al. 2017a). Finally, 425 
children also had an increased intake of phytosterols, tocopherols and polyphenols following 426 
hazelnut consumption. Consequently, in light of the recognized activity of phenolic compounds as 427 
potential modulators of the microbiota (Valdes et al. 2015), the contribution of these bioactives on 428 
bacterial fermentation in the gut cannot be excluded. 429 
Numerous human trials in the recent years have included profiling of the intestinal microbiota 430 
and identification of the expansion or depletion of specific taxa as potential markers for 431 
pathological conditions or dysfunctions (Knip and Siljander 2016; Miele et al. 2015; Sokol et al. 432 
2008). Nonetheless, only few studies have associated specific gut bacteria to defined 433 
pathophysiological mechanisms (e.g., (Devkota et al. 2012)). This limited knowledge on the 434 
involvement of bacteria in host physiological processes greatly limits the possibility of 435 
understanding the actual biological meaning (if any) of several significant correlations that we 436 
found between specific taxa of the intestinal microbiota and lipidemic profiles. However, a few 437 
speculations can be reached. Interestingly, the variation of OTUs belonging to intestinal bacteria 438 
with recognized anti-inflammatory properties, such as Faecalibacterium prausnitzii (Sokol et al. 439 
2008) and Akkermansia muciniphila (Zhao et al. 2017), correlated inversely with changes in TG, 440 
TC, LDL-C, and non-HDL cholesterol, suggesting the potential involvement of these bacteria in the 441 
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link between inflammation and hyperlipidemia (Feingold and Grunfeld 2000; Tall and Yvan-442 
Charvet 2015). Reportedly, Faecalibacterium prausnitzii is inversely associated with inflammatory 443 
bowel diseases and its supplementation abolished inflammation (Sokol et al. 2008). Furthermore, 444 
the abundance of Akkermansia muciniphila is lower in obesity and diabetes than in healthy controls, 445 
and administration of this bacterium has been shown to reduce obesity, fat mass inflammation and 446 
plasma cholesterol and triglycerides (Everard et al. 2013; Plovier et al. 2017). This last example is 447 
also in accordance with the present study, where the changes in some plasma lipids were inversely 448 
associated with this intestinal commensal. In addition, the change of Bacteroides fragilis, which is 449 
another species with a reported potential anti-inflammatory role in the gut (Troy and Kasper 2010), 450 
was inversely correlated with the modification of triglyceridemia. In contrast, we found a direct 451 
correlation between the variations of cholesterolemia and an OTU ascribed to Veillonella dispar, 452 
which is a potential pathobiont associated with several clinical cases of infection (Houston et al. 453 
1997; Marchandin et al. 2001). V. dispar was also found to be enriched in colorectal carcinoma in 454 
adenoma (Kasai et al. 2016). 455 
Conclusions 456 
The results of this study support the hypothesis that young individuals with primary hyperlipidemia 457 
possess an altered (dysbiotic) intestinal microbial ecosystem, which could plausibly contribute to 458 
the abnormal lipid profile of these subjects. A limitation of this study is the small sample size, 459 
which may reduce the potential robustness of the obtained results. Moreover, further studies 460 
focusing on the mechanisms involved in such hypothesized associations are warranted. 461 
Last few years, several in vitro and in vivo studies have demonstrated the ability of nut intake to 462 
modulate the abundance of specific microbial taxa of the gut microbiota and change the intestinal 463 
concentration of SCFAs (Burns et al. 2016; Liu et al. 2016; Mandalari et al. 2010; Schlormann et 464 
al. 2016; Ukhanova et al. 2014). Nonetheless, this research was mostly focused on almonds, and to 465 
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the best of our knowledge, only one study investigated hazelnuts, showing an increase in butyrate 466 
through in vitro fermentation of a human fecal sample (Schlormann et al. 2016). 467 
In conclusion, our study is the first human trial investigating the potential role of hazelnuts as an 468 
IME modulator, and it specifically suggests that a dietary intervention with hazelnuts as part of a 469 
controlled diet for hyperlipidemia could be an effective and practical strategy to manage this 470 
condition. 471 
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Legends 653 
Fig. 1. Inter-sample ecological diversity based on 16S rRNA gene profiling data of fecal 654 
samples from hyperlipidemic subjects participating in the hazelnut intervention trial and 655 
normolipidemic controls. Principal coordinates analysis of weighted (A) and unweighted (B) 656 
UniFrac distances based on OTU abundances. The first two coordinates (PC1 and PC2) are 657 
displayed with the percentage of variance explained in brackets. In panel B, a bi-plot is represented 658 
showing five of the genera that better describe the diversity among samples. The control group is 659 
significantly different in unweighted UniFrac according to ANOSIM test (p<0.05; number of 660 
permutations=99). 661 
 662 
 663 
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Fig. 2. Intrasample ecological diversity based on 16S rRNA gene profiling data of fecal 664 
samples from hyperlipidemic subjects participating in the hazelnut intervention trial and 665 
normolipidemic controls. A, rarefaction curves obtained using Chao1 index fixing a maximum of 666 
50,000 reads per sample. B, α-diversity analysis based on Chao1 and inverse Simpson indexes. T0, 667 
samples before the hazelnut intervention; T1, samples after the hazelnut intervention. ***, P<0.001 668 
according to Mann-Whitney U (unpaired) test. 669 
 670 
  671 
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Fig. 3. Taxonomic units in fecal samples distinguishing hyperlipidemic from control 672 
subjects. Heat map based on the normalized abundance of OTUs (horizontal axis) for an individual 673 
fecal sample (vertical axis). The figure includes only the OTUs that were significantly different 674 
between hyperlipidemic and control samples through the DESeq2 negative binomial distribution 675 
method. Lachn., Lachnospiraceae; R., Ruminococcaceae.  676 
 677 
  678 
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Fig. 4. Fecal levels of short chain fatty acids and lactate in hyperlipidemic and control 679 
subjects. add, hyperlipidemic subjects not included in the intervention trial; T0, samples before the 680 
hazelnut intervention; T1, samples after the hazelnut intervention. u.d.l., under detection limit. *, p 681 
< 0.05; **, p<0.01, ***, p<0.001 according to Mann-Whitney U (unpaired) test. #, p<0.05 682 
according to Wilcoxon (paired) test. 683 
 684 
Fig. 5. Correlation between lipidemic profile and changes in fecal microbiota composition. 685 
This figure only includes OTUs whose change over the hazelnut intervention significantly 686 
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correlated with at least one lipidemic parameter according to Kendall’s Tau rank correlation. The 687 
colors in the left panel represent the mean of DESeq2-normalized abundances of the OTUs in 688 
control and hyperlipidemic (HL) samples before (T0) and after (T1) the intervention. Asterisks in 689 
the second column indicate the FDR adjusted p values (padJ) calculated with a Wald test on 690 
DESeq2-normalized data to indicate significantly different OTUs between control and HL-T0 691 
samples; *, p<0.05; **, p<0.01; ***, p<0.001. The colors in the right panel represent the R-value of 692 
Spearman’s correlation of the differences over the intervention trial between OTU abundance and 693 
lipidemic parameters. Plus signs are according to Kendall’s Tau rank correlation: +, p<0.05; ++, 694 
p<0.01; +++, p<0.001. 695 
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